NCT07395635Recruiting
Phase II Trial of Immunonutrition in Hepatectomy
Impact of Immunonutrition in Patients Undergoing Hepatectomies for Liver Tumors: A Randomized Controlled Phase II Trial
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
A randomised open labelled study to evalaute the impact of immunonutrition in Patients Undergoing Hepatectomies for Liver Tumors
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 29 Jan 2026
- Start date
- 3 Oct 2025
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Tata Memorial Centre
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07395635
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 3 Oct 2025 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Preoperative severe renal failure (estimated glomerular filtration rate \< 30 ml/min)
- History of hypersensitivity to arginine, omega-3 fatty acids, or nucleotide 3. Inability to take oral nutrition
- 4\. Pregnancy 5. Mental condition rendering the subject unable to understand the nature, endpoints and consequences of the trial
Who the study is looking for
- Patients with liver tumors planned for major hepatectomies (defined as resection of \>/= 3 liver segments)
- Age above 18 years
- ASA class I-III
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr.Shraddha Patkar Coordinator of this site? Confirm its status | Mumbai | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.